SAM
KRYS icon

SEB Asset Management’s Krystal Biotech KRYS Stock Holding History

SEB Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14M Sell
37,731
-8,612
-19% -$2.57M 0.05% 289
2026
Q1 		$12M Buy
+46,343
New +$12.3M 0.05% 286

Other funds holding KRYS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

SEB Asset Management's KRYS Position: Q2 2026 in Review

SEB Asset Management reduced its Krystal Biotech (KRYS) stake by 19% in Q2 2026, selling an estimated $2.57M and leaving 37,731 shares worth $14M. The position accounts for 0.05% of the portfolio, ranked #289.

SEB Asset Management first reported a position in KRYS in Q1 2026 and has held it in 2 quarters since. 398 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • SEB Asset Management held 37,731 shares of Krystal Biotech worth $14M as of Q2 2026.
  • SEB Asset Management sold 8,612 Krystal Biotech shares in Q2 2026, an estimated $2.57M.
  • Krystal Biotech made up 0.05% of SEB Asset Management's portfolio in Q2 2026, its #289 holding.
  • SEB Asset Management first reported a position in Krystal Biotech in Q1 2026 and has held it in 2 quarters since.
  • 398 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.